NIPH Clinical Trials Search

Evaluation of the anticoagulant effect in Teneligliption in type 2 diabetic patients

Basic Information

Recruitment status	Complete: follow-up complete
Health condition(s) or Problem(s) studied	Type 2 Diabetes Mellitus
Date of first enrollment	2025/05/01
Target sample size	10
Countries of recruitment	Japan
Study type	Interventional
Intervention(s)	Teneligliptin 20mg/day for 6 months

Outcome(s)

Primary Outcome	HbA1c, pre- and post-prandial(1,2hours)blood glucose, pre-and post-prandial(1,2hours)lipid, pre-and post-prandial(1,2hours)insulin, pre- and post-prandial(1,2hours)proinsulin, pre- and post-prandial(2hours)PAI-1
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	20years-old
Age maximum	Not applicable
Gender	Male and Female
Include criteria
Exclude criteria	"1)Type I diabetes, the diabetes which arose according to the obstacle of the pancreas, or secondary diabetes patients (Cushing syndrome, tip hypertrophia, etc.) "2)Patient who corresponds to contraindications with the package leaflet of Teneligliptin "3)Patient with an excessive habitual drinking 4)Pregnant and breast-feeding "5)Patients judged by the research responsibility (assignment) doctor to be ineligible for some other reason